Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — Technical Presentation (September 2024)
17 slides from Fresenius Medical Care's technical presentation, Sep 16, 2024
Slide 1: Expert call | HDF: High-volume hemodiafiltration
Presentation Franklin W. Maddux, MD Global Chief Medical Officer Member of the Management Board September 16, 2024 Expert call | HDF High-volume hemodiafiltration
Slide 2: Safe harbor statement
Safe harbor statement: In this Safe harbor statement, “the Company” and “Fresenius Medical Care” refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conve
Slide 3: How it works: HD vs. HDF FME product innovation Clinical benefits
1 How it works: HD vs. HDF 2 FME product innovation 3 Clinical benefits 4 CONVINCE Study 5 FME real-world experience 6 Bringing HDF to the U.S.
Slide 4: Basic principle of hemodialysis (HD) | Diffusion
Basic principle of hemodialysis (HD) | Diffusion Hemodialysis ▪ In HD, blood is filtered outside of the body through a Air trap and dialyzer (“artificial kidney”) that comprises a large pressure monitor number of hollow fibers Filtered blood ▪ Blood flows into the fibers while dialysis fluid (“dialy
Slide 5: Different types of hemodialysis (HD) treatments
Different types of hemodialysis (HD) treatments Typical HD | All based on diffusion HDF | A distinct, innovative therapy Low Flux ▪ Hemodiafiltration (HDF) brings the clearance profile closer ▪ Small pores and low water permeability to natural kidney function ▪ Good for diffusive clearance and often
Slide 6: HDF | Diffusion and convection act together to improve solute removal
HDF | Diffusion and convection act together to improve solute removal Goal to remove key toxins while maintaining albumin levels Fiber cross section view Dialysate Hollow fiber HD Diffusion HDF | Diffusion + Convection Urea (60 Dalton) Creatinine (113 Dalton) Beta 2 Microglobulin (11,800 Dalton) Alb
Slide 7: Different forms of HDF
Different forms of HDF Post-dilution, high-volume HDF most efficient with proven benefits What difference does the form of HDF make? ▪ Different forms of HDF exist: pre-, mid-, Filtered convection volume mixed- and post-dilution (20-30% of blood flow) ▪ Post-dilution is the most efficient Substituti
Slide 8: FME has led the world in innovation making high-volume HDF practical, safe, and effective
FME has led the world in innovation making high-volume HDF practical, safe, and effective Requirements for high-volume HDF HDF-capable machines and dialyzers the latest in a long history of FME innovation in renal space Machine designed for high-volume HDF Appropriate dialyzers Vascular access Ultra
Slide 9: Clinical benefits of high-volume HDF
Clinical benefits of high-volume HDF Improved survival Improved patient Decreased intradialytic reported outcomes hypotension HDF convection volume Improved removal of ≥23L/session Improved nutritional key toxins status Decreased inflammatory markers such as CRP Better anemia control HDF Expert Call
Slide 10: History of trials comparing HD vs. HDF
History of trials comparing HD vs. HDF Randomized clinical trials history 2012 Contrast Study1 Turkish HDF Study2 2013 ESHOL Study3 2017 FRENCHIE Study4 2023 CONVINCE Study5 1 Grooteman et al. JASN (2012) 23: 1087-1096, 2 Ok E et al. NDT (2013) 28: 192-202, 3 Maduell et al. JASN (2013) 24(3) :487-97
Slide 11: CONVINCE Study | High-volume HDF reduces mortality
CONVINCE Study | High-volume HDF reduces mortality A pragmatic, multinational, randomized, controlled trial Primary objective Primary outcome To compare HDF when delivered consistently in high-dose (volume), with high flux HD treatment in terms of all-cause mortality 23% mortality rate reduction 1,3
Slide 12: CONVINCE Study | High-volume HDF improves quality of life
CONVINCE Study | High-volume HDF improves quality of life Health-related quality of life Secondary objective Secondary outcome To compare HDF when delivered consistently in high-dose (volume) with high flux HD treatment regarding health-related quality of life ▪ HDF positively affects the health-rel
Slide 13: FME experience with HDF for >20 years
FME experience with HDF for >20 years Real-world experience confirms CONVINCE findings FME clinical data Real-world data analysis evaluating the impact of HDF (compared to HD) on 22% Reduction in mortality outcomes all-cause mortality 31% Reduction ▪ 23 countries in CVD mortality ▪ 661 FME centers ▪
Slide 14: Globally, HDF has grown more than any other therapy in the last 10 years
Globally, HDF has grown more than any other therapy in the last 10 years HDF patient development globally (in K)1 ▪ HDF is available in more than 90 countries, but 502 not yet the U.S. +13% CAGR 447 ▪ More than 4,000 scientific publications available 418 374 on the therapy 346 329 ▪ In Europe and ot
Slide 15: HDF expansion | FME bringing a new standard of care to the U.S.
HDF expansion | FME bringing a new standard of care to the U.S. Leveraging benefits of an integrated company Broad commercial launch of HDF in the U.S. planned for late 2025 Care Delivery ▪ Opportunity to positively affect quality of life, improveto Opportunity outcomes, reduce ▪ April 2023 | FDA ap
Slide 16: Your questions are welcome
Your.questions are welcome x
Slide 17: Contacts
Contacts Fresenius Medical Care AG Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v. d. H. Germany Dr. Dominik Heger Ilia Kuerten Alicia Cahill Head of Investor Relations Vice President Senior Director ir@freseniusmedicalcare.com and Investor Relations Investor Relations Head of Investor
Fresenius Medical Care — Technical Presentation (September 2024) on 6ix